Disclaimer: This isn’t funding advise. PLEASE DO YOUR OWN RESEARCH !!!!
I wrote this submit this morning (CEST) when the inventory value was round 73-74 EUR. I then needed to run some errands earlier than with the ability to submit and the inventory value moved already considerably. All calculations and many others. are based mostly on a inventory value of 73,50 EUR.
By coincidence, I simply wrote about Biontech a couple of weeks in the past. Fortunately my abstract again then was to not make investments:
Now two issues occurred yesterday on March tenth, once they have been supposed to speak about Q2 earnings:
- The 2 founders introduced that they may depart by the top of 2026 in an effort to begin a brand new firm
- The share value dropped considerably after the announcement
That is the inventory chart in Germany (in EUR):
After a low of round 68 EUR, the shares at the moment commerce at 73-74 EUR on the time of writing.
Funnily sufficient, that is virtually precisely the present internet money per share and even 10% beneath my “worst case” assumption:
Utilizing my “outdated” situation, the potential upside would now be clearly loads larger.
However, and this can be a BIG BUT: With the founders leaving, one of many major qualitative arguments turned loads weaker. This was my Professional & Con record again then:
We simply don’t know who will run the corporate from subsequent 12 months onwards. Initially this was a giant adverse information for me.
What did the founders truly announce:
I haven’t listened to the decision but, so I persist with the slide from the outcomes presentation from yesterday:
So Sahin and his spouse will depart by the top of the 12 months and principally take some (or most ?) of the mRNA know-how in alternate for a minority stake into a brand new firm. We have no idea if additionally they get money or not. I’d assume not.
Usually, one sees such “offers” solely after a Biotech firm is taken over by a giant Pharma firm and a founder wands to make it possible for early stage tasks should not getting killed.
One such state of affairs was the Actelion/Idorsia Particular Scenario I invested 9 years in the past, the place after the take-over of Actelion by Johnson & Johnson, the founder Clozel took the entire improvement division together with the early stage pipeline into a brand new firm referred to as Idorsia which was then spun-off to shareholders.
Apparently, Idorsia, even after 9 years didn’t do too effectively and trades considerably beneath the worth proper after the spin-off:
Within the German press, there are some rumors that the founders have made that transfer as a result of a sale of Biontech to a much bigger Pharma firm is perhaps imminent, though formally the founders have mentioned this isn’t the case.
What I discover most hanging is the problem that they haven’t introduced a successor for the founders but.
With out a potential sale of Biontech on the horizon, the founders might have simply “employed” or promoted somebody to CEO who takes care of commercializing the late stage pipeline and proceed to do their analysis inside Biontech.
I get the impression that perhaps, after 18 years, the billionaire Strüngemann Brothers who put up the preliminary funding and nonetheless personal 40% don’t agree anymore with the founders who personal round 15%. In some older articles, each the Strüngmanns and Sahin all the time made the purpose that they wish to create a “full blown” BioPharma firm that may play within the first league internationally.
A minimum of Sahin and his spouse now determined that they really favor to do analysis.
One other dicey challenge is that the founders will principally negotiate the switch of the mRNA know-how with themselves as they wish to shut this earlier than the top of the subsequent quarter, perhaps particularly earlier than a brand new CEO is put in. My impression is that they’re trustworthy folks and actually excited about analysis, however it’s after all not excellent in the event that they negotiate with themselves.
Additionally the announcement that Biontech will solely get a minority share appears to point that this time, Sahin and his spouse wish to have the total management which they at the moment don’t have.
Will probably be additionally attention-grabbing to see if and what number of of Biontech’s R&D workers will observe them to the brand new firm.
What’s the price of a charismatic founder ?
Yesterday’s announcement can also be an attention-grabbing datapoint concerning the query: What’s the price of a charismatic founder? On this case, for many shareholders, the announcement was clearly a giant shock.
The -20% clearly point out that not less than within the quick time period, traders suppose that the corporate is price much less with out its founders.
So what about Biontech now ?
As I discussed at first, the share value is now round -25% decrease than in January. However, with out the founders, lots of issues could possibly be tougher, particularly if lots of people observe them to the brand new firm..
As a compensation, the potential of a take-over/sale of the corporate to a big worldwide participant has clearly elevated, I’d assume that within the case of a takeover, the pipeline worth can be paid to a big extent by an acquirer.
I’ve requested numerous variations of LLMs who the almost definitely acquirer can be. The favorites have been Merck (US), Bristol Myers (with which they partnered) and Roche. All of them might make use of Biotech’s pipeline and have the means to do the transaction.
I additionally suppose that after the mRNA deal is signed, a subsequent sale of the corporate might occur relatively before later.
New situation:
My new draw back case can be 80% of internet money which is a stage that many loss making Biotech corporations commerce at.
My upside situation can be the 144 EUR with the pipeline worth from the final submit.
If I exploit a 50/50 situation this could translate into (-20%+100%)/2= +40%
That appears loads higher than in January.
In fact anybody might add lots of different circumstances however I wish to hold it easy.
There may be nonetheless the problem that we don’t have a “laborious” deadline for a possible deal, however alternatively, the 12 months finish deadline for his or her exit could possibly be interpreted as a deadline for the Strüngmanns to discover a purchaser.
Playbook:
My assumption is that this case doesn’t escalate completely between the founders and the Strüngmann brothers. One huge warning signal and purple flag can be, if the settlement for the brand new firm wouldn’t be signed till the top of June.
Abstract:
In a nutshell, Biontech now seems to be rather more like an attention-grabbing “Particular state of affairs” than in late January.
Sure, the founders will likely be passed by 12 months finish, however the inventory is 25% cheaper and we now have a “comfortable deadline” for a possible M&A announcement.
My “again of the envelope” calculation signifies and anticipated common return of 40% for roughly one 12 months which is engaging. I subsequently allocate 1,5% of the portfolio into Biontech at present costs of 73,50 EUR/Share.
Bonus Soundtrack:
I think about that the founders will play that Soundtrack if the stroll into their new firm in 2027: Jon Batiste – Freedom